A case of a 7-year-old male with epilepsy who developed non-convulsive status epilepticus (NCSE) with electroclinical features consistent with those of atypical absence seizures after adjunctive antiepileptic therapy of tiagabine (TGB) is reported. The patient had frequent generalised and rare partial seizures with generalised epileptic discharges on prior electroencephalogram (EEG) recordings. NCSE was developed when rapid dosage increase and high dose of TGB was given. This case emphasises the need for close monitoring of children with epilepsy taking TGB for exacerbation of seizures or development of NCSE.
INTRODUCTION
Tiagabine (TGB) is a GABA-uptake inhibitor increasing the effect of GABA and may exacerbate some types of seizures, particularly absences and myoclonic seizures 1 . Recently, a number of cases of non-convulsive status epilepticus (NCSE) associated with TGB have been reported in patients with chronic partial epilepsy and in one patient with idiopathic generalised epilepsy [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . TGB-induced NCSE has been described only in adults and paediatric patients over the age of 12 years. In this report, a child with long-standing NCSE provoked by TGB is reported. To our knowledge, this is the first report of NCSE associated with TGB in children under the age of 12 years.
CASE REPORT
A 7-year-old boy with epilepsy was admitted to our hospital in a confused state. He is the first child of the family and the product of a full-term uncomplicated gestation, labour and delivery. Family history was unremarkable for neurological disorders. The child had a history of infantile spasms and delay in motor and cognitive development. Since the age of 2 years, he suffered from frequent myoclonic seizures and rare atypical absences, tonic, atonic and simple partial seizures of unknown aetiology. The interictal electroencephalogram (EEG) showed generalised sharp waves and/or 2-2.5 Hz spike-wave discharges (SWDs) and the brain magnetic resonance imaging was normal. Before the episode described in the present report, the child had never experienced NCSE or any other type of status epilepticus (SE).
The patient had tried most other antiepileptic drugs without achieving satisfactory control and TGB in addition to sodium valproate was administered. During a 7-month follow-up period, the add-on treatment with TGB in a dose of 0.25-0.40 mg/kg/day reduced the frequency of myoclonic seizures, while there was some increase in the number of atypical absences. As the response to treatment with sodium valproate and TGB was incomplete, TGB was administered in increasing dosages. Dosage was escalated every 6 days by 0.2 mg/kg/day to a maximum of 1 mg/kg/day. Two days after reaching the maximum dose, the boy developed episodes of confusion lasting up to 90 minutes, and finally, 7 days after the onset of these episodes, he manifested continuous blank staring A. Skardoutsou et al. and unresponsiveness and was admitted to our hospital. The ictal EEG showed long runs of irregular generalised 3-3.5 Hz SWDs, which did not resemble the patient's usual EEG findings, consistent with a diagnosis of absence status epilepticus (ASE) (Fig. 1) . The trough blood level of sodium valproate was 100 mg/l (therapeutic range 50-100 mg/l), which was almost unchanged as compared with the concentration measured 12 days earlier. Immediate discontinuation of TGB and intravenous treatment with midazolam was followed by complete and sustained electroclinical remission, indicating a causative role of TGB for NCSE. The patient's EEG recorded 2 days after admission to our hospital did not show any paroxysmal abnormalities. In a follow-up period of 3 years, he has been treated with a combination of sodium valproate and clobazam and the seizure frequency remained unchanged, no NCSE re-occurred and the EEG recordings showed the usual findings.
DISCUSSION
TGB is currently recommended as add-on therapy in adults and children above 12 years with partial epilepsy not satisfactorily controlled with other antiepileptic drugs. Efficacy in other types of epilepsy requires further study and very few studies on the efficacy and safety of TGB in childhood have been published 12 . In symptomatic generalised epilepsies or epilepsies associated with diffuse encephalopathy syndrome, the patients have often multiple seizure types that may respond in different ways to TGB 1, 12 . Although a number of cases of NCSE associated with TGB have been reported [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] , precise evidence for this association from epidemiological studies is lacking 13 . It was also suggested that TGB-related stupor is most probably not epileptic in nature, as EEG tracings have showed diffuse slowing or a pattern different from diffuse synchronous bursts of spike and wave 13 .
Our case had severe epilepsy and therefore NCSE might have occurred spontaneously; however, the temporal relationship between the appearance of NCSE and the high and rapid increase of dose of TGB together with the rapid recovery when TGB therapy was stopped provides strong evidence that NCSE was probably induced from TGB therapy. As ictal EEG recordings in previous reported cases with NCSE associated with TGB were not usually performed during the episodes of NCSE, it was difficult to differentiate between complex partial seizure activity or long-standing atypical absence activity. In this report, the patient developed NCSE with electroclinical features consistent with those of atypical ASE.
There are insufficient data at present to identify risk factors for developing NCSE associated with TGB. Although it was suggested that most of the affected patients had pre-existing generalised SWDs, precipitation of apparent NCSE has also been described without a history of such discharges 10 . In our patient, the majority of seizures were generalised and only generalised epileptic discharges were recorded on previous EEG. In contrast to the observations from clinical trials where an episode of NCSE was more common in patients with known prior SE, only few of the reported cases had a history of former SE 10, 13 . Confirming this pattern, our patient had never experienced SE before.
Case reports of NCSE under TGB suggested a specific role of dose levels, since in these patients symptoms occurred mostly at a high dose of TGB. However, cases of NCSE in patients receiving a low dose of TGB have been reported, suggesting an individual risk threshold of unknown aetiology 10 . Moreover, it was suggested that rapid dosage increase of TGB might have contributed in developing NCSE 13 . In our patient, NCSE developed when high dose and rapid dosage increase of TGB was given. Up to now, there is no evidence that a specific interaction between TGB and other antiepileptic drugs could provoke or facilitate NCSE 9, 10 . Our patient developed NCSE while receiving a combination of TGB and sodium valproate, which is a non-enzyme inducing antiepilepic drug and might have increased the total and/or free concentration of TGB in serum.
The findings in our case suggest that clinicians should beware of the possible occurrence of NCSE in children with epilepsy under the anticonvulsant TGB, especially in those with generalised or multiple seizures, generalised EEG abnormalities, high dose and/or rapid dosage increase of TGB.
